Massachusetts Society of Clinical Oncologists - FDA approves zanubrutinib for Waldenström’s macroglobulinemia

"The voice for cancer physicians and their patients in Massachusetts."

Home
For Professionals
FDA Approvals
FDA approves zanubrutinib for Waldenström’s macroglobulinemia

FDA approves zanubrutinib for Waldenström’s macroglobulinemia

31 Aug 2021 3:22 PM | Katy Monaco (Administrator)

Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinemia (WM). Press Release. August 31, 2021. More information.

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org